Related Experiment Videos
The glycine peak in brain diseases
1Department of Radiology, Ege University Hospital, Bornova, Izmir 35100, Turkey. rnsener@hotmail.com
Summary
This study found a distinct glycine peak at 3.50 ppm in brain disease patients using MRI. This finding may indicate excitotoxic brain damage or neurotransmitter disturbances in various neurological conditions.
Area of Science:
- Neuroscience
- Medical Imaging
- Biochemistry
Background:
- Glycine functions as an excitatory neurotransmitter in the brain.
- Previous research identified a glycine peak at 3.52 ppm in laboratory settings and 3.50 ppm in a clinical case.
Purpose of the Study:
- To investigate brain diseases associated with a detectable glycine peak.
- To confirm the in vivo spectral signature of glycine using clinical MRI.
Main Methods:
- Proton magnetic resonance spectroscopy (MRS) was performed on a 1.5 T clinical MRI unit.
- A pure glycine solution was analyzed, and nine patients with various neurological diseases were studied using two-dimensional chemical shift spectroscopy (hybrid CSI).
- Ten healthy individuals served as controls.
Main Results:
- A distinct glycine peak was consistently observed at 3.50 ppm in the clinical MRI experiment.
- This glycine peak was detected in patients with infarction, high-grade astrocytoma, leukoencephalopathies, Leigh's disease, adrenoleukodystrophy, congenital muscular dystrophy, Rasmussen's encephalitis, gliosis, and tuberous sclerosis.
- No glycine peak was observed in the control group.
Conclusions:
- Glycine exhibits a characteristic peak at 3.50 ppm in vivo, distinguishable from myoinositol.
- The presence of glycine in diverse brain pathologies suggests excitotoxic damage or altered neurotransmission mechanisms.